EarningsQ2 2026 Earnings Report
CLVSF Q2 2026 EPS Results
Actual EPS$0.14
Consensus EPS$0.13
Beat/MissBeat by +<$0.01
One Year Ago EPS$0.16
CLVSF Q2 2026 Revenue Results
Actual Revenue$19.89M
Expected Revenue$18.32M
Beat/MissBeat by +$1.57M
YoY Revenue Growth+4.47%
Earnings Announcement Details
QuarterQ2 2026
Date07/17/2026
TimeBefore Open
Conference CallFriday, July 17, 2026
CLVSF Upcoming Earnings
CellaVision AB's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
CLVSF Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a generally positive operational and commercial picture: solid top-line growth (4.5% YoY; ~6% organic), record Americas performance (+≈59% in Americas sales), healthy margins (70% gross margin; 27% EBITDA margin) and progress on strategic initiatives (Bone Marrow launch, FDA 510(k) process, FPM development). Offsetting risks include APAC weakness (notably China), a distributor inventory adjustment in EMEA that depressed near-term sales, increased working capital leading to a negative total cash flow for the quarter, one-time CEO transition costs (SEK 9m) and temporary operational disruptions (SEK 2m delayed reagents). On balance, the positives — strong regional recovery in the Americas, product/reagent momentum in key markets, continued R&D investment and a solid cash buffer — outweigh the transitory and region-specific headwinds.Company Guidance
Revenue Growth and Organic Expansion
Net sales of SEK 200 million in Q2 2026, reported up ~4.5% year-over-year; management also cited ~5.6%–6% organic growth with a ~1.1% FX headwind.
Record Americas Performance
Americas reached an all-time high with sales of SEK 105 million versus SEK 66 million in Q2 2025 (≈ +59%), driven by large instrument sales, tender wins and instrument refreshes in mid-size and large laboratory networks.
Strong Profitability
EBITDA of SEK 55 million and a 27% EBITDA margin for the quarter; gross margin of 70%. Adjusted for SEK 9 million CEO-transition expenses, EBITDA and margin increased versus the prior year quarter.
Product-Line Momentum
Instruments sales SEK 113 million (up ~7%); reagents sales SEK 42 million (up ~11%), with recurring reagent growth notably in Japan and Australia; software & other sales SEK 46 million (noted timing lag vs instrument installs).
Commercial Launch of Bone Marrow Application and FDA Progress
Commercial BMA (Bone Marrow Aspirate) launch in EMEA with encouraging initial customer interest and sales; ongoing FDA 510(k) registration process targeting clearance in the U.S. before year-end. Management expects BMA to contribute ~1–2 percentage points to growth by year-end.
FPM Platform and R&D Commitment
Development of FPM technology progressing through development phases; R&D investment remains high at ~22% of net sales, supporting confidence in FPM as a platform for future hematology and adjacent markets (pathology, cytology).
Liquidity and Cash Position
Operating cash flow of SEK 29 million and cash & cash equivalents of SEK 172 million on the balance sheet, indicating a robust financial position despite quarterly outflows.
CLVSF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed